Adressen van TCM artsen en acupunctuur staan in dit artikel: 

https://kanker-actueel.nl/adressen-van-betrouwbare-tcm-artsen-en-acupuncturisten.html

19 september 2016: lees ook dit artikel: 

https://kanker-actueel.nl/NL/tcm-traditionele-chinese-medicijnen-naast-westerse-medicijnen-voor-gevorderde-niet-kleincellige-longkanker-geeft-langere-levensduur-betere-kwaliteit-van-leven-in-vergelijking-met-alleen-westerse-medicijnen.html

8 juni 2016: Bron: Complement Ther Med. 2016 Feb;24:55-62. doi: 10.1016/j.ctim.2015.12.006. Epub 2015 Dec 17

Wanneer patienten met vergevorderde niet-klein-cellige longkanker als onderhoudsbehandeling TCM - Traditionele Chinese Medicijnen krijgen in plaats van chemo (docetaxel, pemetrexed of gemcitabine) dan hebben deze patienten een veel betere kwaliteit van leven. Bovendien stijgt de mediane overall overleving met ca. 3 maanden (21.5 maanden vs. 18.8 maanden, P=0.601) en blijken er op 1-jaars meting meer mensen nog in leven (78.1% vs. 53.1%, P=0.035). 

Dit blijkt uit een gerandomiseerde fase II studie bij totaal 71 patiënten met vergevorderde niet-kleincellige longkanker waarvan er 64 konden worden geëvalueerd omdat er 7 patiënten niet aan de toelatingscriteria voldeden. Of artsen hier in het westen deze studie accepteren betwijfel ik want er is een vloeistof gebruikt van kikkerhuid voor de injecties. Injecties die overigens al jarenlang worden gebruikt met name bij longkanker, zie verderop studies daarmee gedaan.

Bufo bufo gargarizans Cantor

Foto: Bufo bufo gargarizans

Studieresultaten:

In deze gerandomiseerde studie werden 64 patiënten met niet-klein-cellige longkanker opgenomen die in eerste instantie goed reageerden op een standaardbehandeling. De 64 patienten werden 1 op 1 gerandomiseerd ingedeeld in twee groepen: een TCM groep werd behandeld met een Chinees kruid via een injectie (Cinobufacini, 20 ml/d, d1–d10), een afkooksel van verschillende kruiden (d1–d21) en een Chinese acupunture applicatie (d1–d21), n = 32). De tweede groep kreeg alleen chemotherapie (of met Alimta -  pemetrexed (non-squamous NSCLC, 500 mg/m2, d1) en docetaxel (75 mg/m2, d1) of met gemcitabine (1250 mg/m2, d1 and d8), n  = 32). Een behandelingskuur durude 21 dagen.  De kuren werden herhaald tot zich progressie voordeed of ontoelaastbare bijwerkingen gaf of op verzoek van de patient om te stoppen emt de behandeling.Primaire doel was tijd tot zich progressie voordeed. Secondaire doelen waren kwaliteit van leven, 1-jaars overleving en overall overleving.

Hier een grafiek van de deelnemers verdeeld over de twee groepen:

TCM studie bij longkanker

Resultaten:

Een TCM behandeling verlengde de tijd tot zich progressie voordeed met enkele weken meer dan voor de chemogroep. (3.0 maanden vs. 2.3 maanden, P = 0.114). Mediane overall overleving werd ca. 3 maanden langer maar was niet statistisch significant (21.5 maanden vs. 18.8 maanden, P = 0.601). 1-jaars overleving was daarentegen wel statistisch significant in het voordeel van de TCM groep:  (78.1% vs. 53.1%, P  = 0.035). Ook bleek de kwaliteit van leven getoetst aan de EORTC QLQ-C30 en EORTC QLQ-LC13 QOL tabellen statistisch significant beter voor de TWM groep in vergelijking met de chemogroep.

TCM studie bij longkanker OS grafiek

Conclusie:

Een onderhoudsbehandeling met TCM - Traditionele Chinese Medicijnen had hetzelfde effect op tijd tot zich progressie voordeed maar verbeterde de 1-jaars overleving en kwaliteit van leven. Een TCM onderhoudsbehandeling kan dus een verdedigbare behandelingsoptie zijn voor patienten met gevorderde niet-klein-cellige longkanker op moment dat sprake is van stabiele ziekte door chemotherapie. 


Het volledige studierapport: Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial is gratis in te zien. Er ook aan toegevoegd de referentielijst die is gebruikt bij deze studie.

En zie ook deze reviewstudie van de effecten van de vloeistof van kikkerhuid in deze studie bij niet-kleincellige longkanker: Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy.

Hier het abstract van de studie hirboven beschreven:

TCM maintenance treatment had similar effects on TTP and OS compared with maintenance chemotherapy, but it improved patients' QOL and had higher 1-year survival rate. TCM Maintenance treatment is a promising option for advanced NSCLC patients without progression following first-line chemotherapy.

Complement Ther Med. 2016 Feb;24:55-62. doi: 10.1016/j.ctim.2015.12.006. Epub 2015 Dec 17.

Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.

Jiang Y1, Liu LS2, Shen LP3, Han ZF4, Jian H5, Liu JX6, Xu L7, Li HG8, Tian JH9, Mao ZJ10.

Author information

Abstract

OBJECTIVES:

Maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) is an increasingly hot topic in the field of clinical NSCLC research. This study aimed to evaluate the effects of Traditional Chinese Medicine (TCM) treatment as maintenance therapy on time to progression (TTP), quality of life (QOL), overall survival (OS) and 1-year survival rate in patients with advanced NSCLC.

METHODS:

This study was conducted as a randomized, controlled, open-label trial. 64 non-progressive patients who responded to initial therapy were randomized 1:1 to the TCM arm (treated with herbal injection (Cinobufacini, 20ml/d, d1-d10), herbal decoction (d1-d21) and Chinese acupoint application (d1-d21), n=32) or to the chemotherapy arm (treated with pemetrexed (non-squamous NSCLC, 500mg/m(2), d1), docetaxel (75mg/m(2), d1) or gemcitabine (1250mg/m(2), d1 and d8), n=32). Each therapy cycle was 21 days. They were repeated until disease progression, unacceptable toxicity, or until the patients requested therapy discontinuation. The primary end point was TTP; the secondary end points were QOL, OS and 1-year survival rate. "Intention-to-treat" analysis included all randomized participants.

RESULTS:

TCM treatment prolonged median TTP for 0.7 months compared with chemotherapy, but it was not statistically significant (3.0 months vs. 2.3 months, P=0.114). Median OS time for TCM treatment did not offer a significant advantage over for chemotherapy (21.5 months vs. 18.8 months, P=0.601). 1-year survival rate of TCM treatment significantly improved than that of chemotherapy (78.1% vs. 53.1%, P=0.035). TCM treatment can significantly improve QOL when compared to chemotherapy as assessed by EORTC QLQ-C30 and EORTC QLQ-LC13 QOL instruments.

CONCLUSIONS:

TCM maintenance treatment had similar effects on TTP and OS compared with maintenance chemotherapy, but it improved patients' QOL and had higher 1-year survival rate. TCM Maintenance treatment is a promising option for advanced NSCLC patients without progression following first-line chemotherapy.

Copyright © 2015 Elsevier Ltd. All rights reserved.

References

  1. Scagliotti, G.V., Marinis, F.D., Rinaldi, M. et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 4285–4291
  2. Schiller, J.H., Harrington, D., Belani, C.P. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–98
  3. Fidias, P.M., Dakhil, S.R., Lyss, A.P. et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 591–598
  4. Gerber, D.E. and Schiller, J.H. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013; 31: 1009–1020
  5. Rinaldi, M., Belvedere, O., Cauchi, C., Defferrari, C., Viola, G., and Grossi, F. Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol. 2006; 17: ii67–ii70
  6. Grossi, F., Aita, M., Foilador, A. et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review for the literature. Oncologist. 2007; 12: 451–464
  7. Gridelli, C., Maione, P., Rossi, A. et al. Potential treatment options after first-line chemotherapy for advanced non-small cell lung cancer: maintenance treatment or early second-line?. Oncologist. 2009; 14: 137–147
  8. Brodowicz, T., Krakowski, M., Zwitter, M. et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006; 52: 155–163
  9. Ciuleanu, T., Brodowicz, T., Zielinski, C. et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432–1440
  10. Paz-Ares, L., De Marinis, F., Dediu, M. et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet. 2012; 13: 247–255
  11. Paz-Ares, L., De Marinis, F., Dediu, M. et al. Paramount: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2895–2904
  12. Chen, Z.F., Li, C.Z., and Liu, S.X. Meta-analysis on primary non-small cell lung cancer treated by TCM. J TCM. 1999; 40: 287–289
  13. Liu, J.X., Shi, Z.M., Xu, Z.Y. et al. Studies on late primary adenocarcinoma of lung treated methods of nourishing Yin to replenish fluid and warming Yang to benefit Qi. J TCM. 1995; 36: 155–158
  14. Lin, L.Z., Zhou, D.H., and Zheng, X.T. Effect of Traditional Chinese Medicine in improving quality of life of patients with non-small cell lung cancer in late stage. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 2006; 26: 389–393
  15. Tian, J.H., Liu, L.S., Shi, Z.M., Zhou, Z.Y., and Wang, L. A randomized controlled pilot trial of Feiji Reipe on quality of life of non-small cell lung cancer patients. Am J Chin Med. 2010; 38: 15–25
  16. You, J., Shi, Z.M., Han, B.H., and Ding, J.F. Evaluation on effect of feiji recipe on quality of life of patients with non-small-cell lung cancer by adopting international questionnaire of QOL. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 2006; 26: 33–37
  17. Guo, H.R., Liu, J.X., Xu, L., Madebo, T., and Baak, J.P. Traditional Chinese Medicine Herbal Treatment May Have a Relevant Impact on the Prognosis of Patients With Stage IV Adenocarcinoma of the Lung Treated With Platinum-Based Chemotherapy or Combined Targeted Therapy and Chemotherapy. Integr Cancer Ther. 2011; 10: 127–137
  18. National Collaborating Centre for Acute Care. Lung Cancer: the Diagnosis and Treatment of Lung Cancer. National Institute for Clinical Excellence, London; 2005
  19. Zheng, X.Y. The Guiding Principles of Clinical Research of New Chinese Medicine (Trial). Chinese Medical Science and Technology Press, Beijing; 2002 (Chinese)
  20. Shanghai Municipal Public Health Bureau. Shanghai Diagnosis and Treatment Routine of Tcm Syndrome. 2nd ed. Shanghai University of Traditional Chinese Medicine Press, Shanghai; 2003 (Chinese)
  21. Park, J.O., Kim, S.W., Ahn, J.S. et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25: 5233–5239
  22. Scagliotti, G.V., Parikh, P., von Pawel, J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543–3551
  23. Stinchcombe, T.E. and Socinski, M.A. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thoracic Oncol. 2009; 4: 243–250
  24. Soon, Y.Y., Stockler, M.R., Askie, L.M., and Boyer, M.J. Duration of chemotherapy for advanced non-small-cell lung cancer: asystematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27: 3277–3283
  25. Lam, Y.C., Cheng, C.W., Peng, H., Law, C.K., Huang, X., and Bian, Z. Cancer patients’ attitudes towards Chinese medicine: Hong Kong survey. Chin Med. 2009; 4: 25
  26. Bridges, J.F., Mohamed, A.F., Finnern, H.W., Woehl, A., and Hauber, A.B. Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012; 77: 224–231
  27. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252–264

This study demonstrated the efficacy of Huachansu combined with chemotherapy in the treatment of advanced NSCLC. However, limitations exist and high-quality trials are needed for further verification.

Evid Based Complement Alternat Med. 2015;2015:408145. doi: 10.1155/2015/408145. Epub 2015 Aug 11.

Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy.

Zhou B1, Wu F2, Yuan L3, Miao Z4, Zhu S1.

Author information

Abstract

Background. Huachansu, the sterilized water extract of Bufo bufo gargarizans toad skin, is used in China to alleviate the side-effects and enhance the therapeutic effect of chemotherapy in advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to assess Huachansu's efficacy. Methods. We extensively searched electronic databases (CENTRAL, EMBASE, MEDLINE, CBM, Cochrane Library, CNKI, CEBM, WFDP, CSCD, CSTD, and IPA) for randomized controlled trials containing Huachansu plus chemotherapy as the test group and chemotherapy as the control group. Seventeen trials were selected based on the selection criteria. The pooled relative ratio (RR) of indicators with 95% confidence interval (95% CI) was calculated for efficacy evaluation. Results. The meta-analysis demonstrated a statistically significant improvement in objective tumor response, one-year survival, Karnofsky performance status, pain relief, and alleviation of severe side-effects (nausea and vomiting, leukocytopenia) in the test group as compared to the control group, but no significant difference in thrombocytopenia. Conclusions. This study demonstrated the efficacy of Huachansu combined with chemotherapy in the treatment of advanced NSCLC. However, limitations exist and high-quality trials are needed for further verification.

PMID:
26347788
PMCID:
PMC4548072

References

1. Molina J. R., Yang P., Cassivi S. D., Schild S. E., Adjei A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings. 2008;83(5):584–594. doi: 10.4065/83.5.584. [PMC free article] [PubMed] [Cross Ref]
2. Zhao H., Wu X., Wang H., et al. Qualitative and quantitative analysis of cinobufacini injection using rapid separation liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry and HPLC-photodiode array detection, a feasible strategy for the quality control of Chinese medicine injections. Journal of Separation Science. 2013;36(3):492–502. doi: 10.1002/jssc.201200762. [PubMed] [Cross Ref]
3. Clarke B. T. The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biological Reviews of the Cambridge Philosophical Society. 1997;72(3):365–379. doi: 10.1017/S0006323197005045. [PubMed] [Cross Ref]
4. Wang D.-L., Qi F.-H., Tang W., Wang F.-S. Chemical constituents and bioactivities of the skin of Bufo bufo gargarizans cantor. Chemistry and Biodiversity. 2011;8(4):559–567. doi: 10.1002/cbdv.201000283. [PubMed] [Cross Ref]
5. Qi F., Li A., Inagaki Y., et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. International Immunopharmacology. 2011;11(3):342–349. doi: 10.1016/j.intimp.2010.12.007. [PubMed] [Cross Ref]
6. Liu L., Chen B.-A., Qin S.-K. Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice. Chinese Journal of Integrated Traditional and Western Medicine. 2011;31(1):67–72. [PubMed]
7. Miao Z. L., Zhang K., Yang M. Z., Zhou X. J. Studies on anti-tumor and enhancing immunity activity of toad coat. China Journal of Chinese Materia Medica. 2010;35(2):211–214. doi: 10.4268/cjcmm20100221. [PubMed] [Cross Ref]
8. Miao Z. L., Zhang K., Bai Q. M., Yang M. Z., Zhou X. J. Textual research on Chantui—a new official Part of Bufo bufo gargarizans Cantor. Lishizhen Medicine and Materia Medica Research. 2006;17(11):2323–2324.
9. Meng Z., Garrett C. R., Shen Y., et al. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. British Journal of Cancer. 2012;107(3):411–416. doi: 10.1038/bjc.2012.283. [PMC free article] [PubMed] [Cross Ref]
10. Bao W. L., Zhang Y. J., Sun Y. Clinical study of the Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Zhejiang Journal of Traditional Chinese Medicine. 2011;46(7):478–479.
11. Cao C. Y. Clinical study of the Huachansu combined with NP regimen in treatment of advanced non-small cell lung cancer. The Journal of Medical Theory and Practice. 2009;22(8):935–936.
12. Ding Y. J. Clinical study of the Huachansu combined with NI regimen in treatment of advanced non-small cell lung cancer. Shandong Medical Journal. 2011;51(9):76–77.
13. Dong J. Clinical observation of the Huachansu combined with NP regimen in treatment of advanced non-small cell lung cancer. Chinese Journal of Traditional Medical Science and Technology. 2013;20(3):p. 304.
14. Hu Z.-H. Clinical observation of cinobufacini injection combined with TP regimen for advanced non-small-cell lung cancer. China Pharmacy. 2012;23(16):1507–1510.
15. Jing E. Clinical study of the Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chinese Remedies & Clinics. 2007;7(5):380–381.
16. Li J. Clinical observation of the Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chinese Journal of Medical Guide. 2011;13(11):1907–1908.
17. Li M., Xu C., Liu X. Clinical observation of Hua Chan Su injection in the adjuvant therapy for 64 patients with non-small cell lung cancer. Tumor. 2007;27(8):666–668.
18. Li X. Y., Zhang X. Y., Yan Y. Q., Pan L. L., Wang Y. J. The effect of the combination program of Huachansu and chemotherapy on patients with non-small-cell carcinoma. China Medcine. 2010;5(8):691–692.
19. Liu B. D. Observe the clinical effect of cinobufacin capsules in the treatment of small cell lung cancer. Journal of Clinical and Experimental Medicine. 2014;13(15):1263–1265.
20. Miao C. L., Yu Q. F., Liang H. F. Clinical observation of the Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chinese Journal of Integrative Medicine. 2007;27(7):657–658.
21. Miao X. D., Cao H. F., Wang W. X. Observation on the short-term efficacy of Huachansu combined with TP regimen in treatment of advanced non-small cell lung cancer. Chinese and Foreign Medical Research. 2014;12(28):130–133.
22. Qi R. F. Clinical observation of the Huachansu in adjuvant treatment of advanced non-small cell lung cancer. The Chinese and Foreign Health Abstract. 2011;8(12):80–82.
23. Wang S. L. Analysis of the therapeutic effect of Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Central Plains Medical Journal. 2006;33(1):p. 70.
24. Xiong L. G., Li L. L. Clinical observation of the Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Practical Oncology Journal. 2005;9(4):294–296.
25. Yang X. F., Xi J. Observation of the therapeutic effect of Huachansu combined with chemotherapy in treatment of advanced non-small cell lung cancer. Herald of Medicine. 2006;25(12):1287–1288.
26. Yu H. Y., Gao S. Y., Hao Y. X. Study of Huanchansu injection combined with TP regimen in the treatment of patients with advanced non-small cell lung cancer. The Practical Journal of Cancer. 2012;27(1):55–57.
27. Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G. Measuring inconsistency in meta-analyses. British Medical Journal. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557. [PMC free article] [PubMed] [Cross Ref]
28. McBride M. C. Bufotenine: toward an understanding of possible psychoactive mechanisms. Journal of Psychoactive Drugs. 2000;32(3):321–331. doi: 10.1080/02791072.2000.10400456. [PubMed] [Cross Ref]
Articles from Evidence-based Complementary and Alternative Medicine : eCAM are provided here courtesy of Hindawi Publishing Corporation

TCM, Chinese kruiden, PAM-V, Yoga, acupunctuur, voeding, voedingsuppletie, vitamines, Qi-Gong, Tai Ji, beweging, Houtsmullerdieet, Moermandieet, Gersondieet, longkanker alle stadia


Plaats een reactie ...

Reageer op "TCM - Traditionele Chinese Medicijnen als onderhoudsbehandeling voor gevorderde niet-kleincellige longkanker geeft langere levensduur en betere kwaliteit van leven in vergelijking met chemo"


Gerelateerde artikelen
 

Gerelateerde artikelen

TCM - Traditionele Chinese >> Shenqi Fuzheng injectie voor >> Ginseng Rg3 naast chemotherapie >> Onderhoudsbehandeling met >> TCM - Traditionele Chinese >> TCM - Traditionele Chinese >> Aanvullende niet toxische >> Chinese kruiden naast chemo >> Feitai capsule maakt dat patiënten >> Feitai capsule met een mix >>